Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$46.4BCash on Hand
CF+ Cash Runway
1.2%Short Interest
$45.74Analyst Target (12)
Follow NVO by emailGet an email when NVO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about NVO, unsubscribe in one click. Privacy
📣 What NVO Says Is Next
H1 2027 · Denecimig: “In the US, the regulatory review of denecimig is still ongoing, and pending regulatory decision, a US launch is expected in H1 2027.”
Company press release, Nov 4, 2026 · SEC filing
Q4 2026 · “The 25 mg dose for Ozempic ® pill was submitted for US FDA approval earlier in the year with an expected FDA decision during Q4 2026.”
Company press release, Aug 4, 2026 · SEC filing
second half of 2026 · “The recommendation also includes data from SELECT which demonstrates that Wegovy® reduces the risk of major adverse cardiovascular events (MACE)*, in the label. · Wegovy® pill is the only oral GLP-1 treatment with no drug-drug restrictions in the label. · Novo Nordisk plans to launch Wegovy® pill in select markets outside the US in the second half of 2026.”
Company press release, May 22, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Shareholder vote Novo Nordisk bought back 225,000 B shares on 13 November 2026 at an average price of DKK 276.25 under its programme. Accumulated buybacks since 6 May 2026 total 28,975,000 shares for DKK 8,318,073,280. Form 6-K · SEC filing
Nov 9, 2026 ·
Shareholder vote Novo Nordisk repurchased 220,000 B shares for DKK 58,974,660 on 6 November 2026 at an average DKK 268.07 under its programme. Cumulative programme purchases reached 27,845,000 shares for DKK 8,008,013,722. Form 6-K · SEC filing
Nov 4, 2026 ·
Earnings Novo Nordisk raised its 2026 outlook as Q3 adjusted operating profit rose 27% at CER to DKK 31,720 million. Reported operating profit fell 9% at CER on DKK 8.7 billion of impairments. Form 6-K · SEC filing
Nov 3, 2026 ·
Shareholder vote Novo Nordisk reported repurchasing 240,000 B shares per day from 26 October to 2 November 2026 at prices of DKK 257.51 to 267.29. Accumulated repurchases under this programme reached 26,955,000 shares for DKK 7,764,364,812. Form 6-K · SEC filing
Oct 26, 2026 ·
Shareholder vote Novo Nordisk reported repurchasing 240,000 B shares daily in the period through 23 October 2026, with 25,515,000 shares bought under the programme initiated 6 May 2026 for DKK 7,387,348,112 accumulated. Treasury holdings reached 54,314,876 B shares, 1.2% of share capital. Form 6-K · SEC filing
Oct 13, 2026 ·
Novo Nordisk reported ongoing share buybacks: 23,090,000 B shares repurchased under the programme since 6 May 2026 for DKK 6,758,876,433, with 5 to 9 October purchases at DKK 246.39 to 254.93 per share. Treasury holdings reached 51,889,876 B shares. Form 6-K · SEC filing
Oct 6, 2026 ·
Novo Nordisk reported share repurchases under a programme started 6 May 2026, with 21,845,000 B shares bought for DKK 6,447,270,879 so far. It holds 50,644,876 treasury shares, 1.1% of share capital. Form 6-K · SEC filing
Oct 5, 2026 ·
Regulatory Novo Nordisk says the FDA review of denecimig for haemophilia A is ongoing with no new timeline for action. The FDA cited facility remediation as the cause, found no efficacy or safety deficiencies, and Novo still aims for a US launch in the first half of 2027. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2026 · N/A · Enrolling · Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol Registry primary completion date, not a results date
Dec 2026 · Phase 1 · Recruiting · Study to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and Acceptance Registry primary completion date, not a results date
Dec 2026 · Phase 1 · Recruiting · Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by… Registry primary completion date, not a results date
Dec 2026 · N/A · Enrolling · Patient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany Registry primary completion date, not a results date
Dec 2026 · N/A · Enrolling · Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma Registry primary completion date, not a results date
Dec 2026 · Phase 1 · Recruiting · A Study Understanding How Much CDR132L Enters the Bloodstream After Injection Under the Skin Compared to Injection Into a Vein in Healthy Participants Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not NVO's own candidates): Sitagliptin, Tirzepatide, Glucagon, Liraglutide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
NVO holds $46.4B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NVO and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.